

## PRESS CLIPPING SHEET

|                      |   |
|----------------------|---|
| <b>PUBLICATION:</b>  | Daily News  |
| <b>DATE:</b>         | 5-August-2015                                       |
| <b>COUNTRY:</b>      | Egypt   |
| <b>CIRCULATION:</b>  | 60,000  |
| <b>TITLE :</b>       | DBK Pharma allocates 35% of capital in stock market |
| <b>PAGE:</b>         | Front Page  |
| <b>ARTICLE TYPE:</b> | Health Corporate News                               |
| <b>REPORTER:</b>     | Rana Yehia  |

### DBK Pharma allocates 35% of capital in stock market

*Company is targeting EGP 100m by producing 66,000 Sovaldi packs*

**By Rana Yehia**

DBK Pharma, a diversified healthcare company that manufactures, develops and distributes therapeutic solutions, recently listed on the Egyptian Stock Exchange (EGX).

The move came to expand the company, to transform it from a family company to an institutional company.

The company's current capital is estimated at EGP 150m, with 35% of the capital allocated in the stock market through about 52m shares, recording approximately EGP 170m with a price of EGP 3.25 per share. The company allocates its shares through Al-Rowad for



Omar Korashi

**DBK CEO Hamdy El-Debieky**

Securities Brokerage Company.

One of the company's main targets in 2016 is to produce Sovaldi, a medication used in the treatment of hepatitis-C, with an amount of production recording 66 packs, realising sales revenues of EGP 100m, according to

DBK CEO Hamdy El-Debieky.

In 2014, the company's sales revenues reached approximately EGP 72m, with a net profit recording around EGP 23m.

While the company is forecasted to reach EGP 100m in sales revenues by the end of 2015, sales reached EGP 35m during the first quarter (Q1) of 2015, with net profits amounting around EGP 10m.

Moreover, 22% of the revenues come from exportation. DBK exports its products to 18 Arab and African countries.

DBK is also planning on establishing two new factories by 2017/2018, with investments amounting to EGP 60m. DBK projects to add 100 new medicines to its production line.